Cargando…

Pharmacogenetics in Primary Headache Disorders

Primary headache disorders, such as migraine, tension-type headache (TTH), and cluster headache, belong to the most common neurological disorders affecting a high percentage of people worldwide. Headache induces a high burden for the affected individuals on the personal level, with a strong impact o...

Descripción completa

Detalles Bibliográficos
Autores principales: Belyaeva, Irina I., Subbotina, Anna G., Eremenko, Ivan I., Tarasov, Vadim V., Chubarev, Vladimir N., Schiöth, Helgi B., Mwinyi, Jessica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866828/
https://www.ncbi.nlm.nih.gov/pubmed/35222013
http://dx.doi.org/10.3389/fphar.2021.820214
_version_ 1784655916918898688
author Belyaeva, Irina I.
Subbotina, Anna G.
Eremenko, Ivan I.
Tarasov, Vadim V.
Chubarev, Vladimir N.
Schiöth, Helgi B.
Mwinyi, Jessica
author_facet Belyaeva, Irina I.
Subbotina, Anna G.
Eremenko, Ivan I.
Tarasov, Vadim V.
Chubarev, Vladimir N.
Schiöth, Helgi B.
Mwinyi, Jessica
author_sort Belyaeva, Irina I.
collection PubMed
description Primary headache disorders, such as migraine, tension-type headache (TTH), and cluster headache, belong to the most common neurological disorders affecting a high percentage of people worldwide. Headache induces a high burden for the affected individuals on the personal level, with a strong impact on life quality, daily life management, and causes immense costs for the healthcare systems. Although a relatively broad spectrum of different pharmacological classes for the treatment of headache disorders are available, treatment effectiveness is often limited by high variances in therapy responses. Genetic variants can influence the individual treatment success by influencing pharmacokinetics or pharmacodynamics of the therapeutic as investigated in the research field of pharmacogenetics. This review summarizes the current knowledge on important primary headache disorders, including migraine, TTH, and cluster headache. We also summarize current acute and preventive treatment options for the three headache disorders based on drug classes and compounds taking important therapy guidelines into consideration. Importantly, the work summarizes and discusses the role of genetic polymorphisms regarding their impact on metabolism safety and the effect of therapeutics that are used to treat migraine, cluster headache, and TTH exploring drug classes such as nonsteroidal anti-inflammatory drugs, triptans, antidepressants, anticonvulsants, calcium channel blockers, drugs with effect on the renin–angiotensin system, and novel headache therapeutics such as ditans, anti-calcitonin-gene-related peptide antibodies, and gepants. Genetic variants in important phase I-, II-, and III-associated genes such as cytochrome P450 genes, UGT genes, and different transporter genes are scrutinized as well as variants in genes important for pharmacodynamics and several functions outside the pharmacokinetic and pharmacodynamic spectrum. Finally, the article evaluates the potential and limitations of pharmacogenetic approaches for individual therapy adjustments in headache disorders.
format Online
Article
Text
id pubmed-8866828
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88668282022-02-25 Pharmacogenetics in Primary Headache Disorders Belyaeva, Irina I. Subbotina, Anna G. Eremenko, Ivan I. Tarasov, Vadim V. Chubarev, Vladimir N. Schiöth, Helgi B. Mwinyi, Jessica Front Pharmacol Pharmacology Primary headache disorders, such as migraine, tension-type headache (TTH), and cluster headache, belong to the most common neurological disorders affecting a high percentage of people worldwide. Headache induces a high burden for the affected individuals on the personal level, with a strong impact on life quality, daily life management, and causes immense costs for the healthcare systems. Although a relatively broad spectrum of different pharmacological classes for the treatment of headache disorders are available, treatment effectiveness is often limited by high variances in therapy responses. Genetic variants can influence the individual treatment success by influencing pharmacokinetics or pharmacodynamics of the therapeutic as investigated in the research field of pharmacogenetics. This review summarizes the current knowledge on important primary headache disorders, including migraine, TTH, and cluster headache. We also summarize current acute and preventive treatment options for the three headache disorders based on drug classes and compounds taking important therapy guidelines into consideration. Importantly, the work summarizes and discusses the role of genetic polymorphisms regarding their impact on metabolism safety and the effect of therapeutics that are used to treat migraine, cluster headache, and TTH exploring drug classes such as nonsteroidal anti-inflammatory drugs, triptans, antidepressants, anticonvulsants, calcium channel blockers, drugs with effect on the renin–angiotensin system, and novel headache therapeutics such as ditans, anti-calcitonin-gene-related peptide antibodies, and gepants. Genetic variants in important phase I-, II-, and III-associated genes such as cytochrome P450 genes, UGT genes, and different transporter genes are scrutinized as well as variants in genes important for pharmacodynamics and several functions outside the pharmacokinetic and pharmacodynamic spectrum. Finally, the article evaluates the potential and limitations of pharmacogenetic approaches for individual therapy adjustments in headache disorders. Frontiers Media S.A. 2022-02-10 /pmc/articles/PMC8866828/ /pubmed/35222013 http://dx.doi.org/10.3389/fphar.2021.820214 Text en Copyright © 2022 Belyaeva, Subbotina, Eremenko, Tarasov, Chubarev, Schiöth and Mwinyi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Belyaeva, Irina I.
Subbotina, Anna G.
Eremenko, Ivan I.
Tarasov, Vadim V.
Chubarev, Vladimir N.
Schiöth, Helgi B.
Mwinyi, Jessica
Pharmacogenetics in Primary Headache Disorders
title Pharmacogenetics in Primary Headache Disorders
title_full Pharmacogenetics in Primary Headache Disorders
title_fullStr Pharmacogenetics in Primary Headache Disorders
title_full_unstemmed Pharmacogenetics in Primary Headache Disorders
title_short Pharmacogenetics in Primary Headache Disorders
title_sort pharmacogenetics in primary headache disorders
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866828/
https://www.ncbi.nlm.nih.gov/pubmed/35222013
http://dx.doi.org/10.3389/fphar.2021.820214
work_keys_str_mv AT belyaevairinai pharmacogeneticsinprimaryheadachedisorders
AT subbotinaannag pharmacogeneticsinprimaryheadachedisorders
AT eremenkoivani pharmacogeneticsinprimaryheadachedisorders
AT tarasovvadimv pharmacogeneticsinprimaryheadachedisorders
AT chubarevvladimirn pharmacogeneticsinprimaryheadachedisorders
AT schiothhelgib pharmacogeneticsinprimaryheadachedisorders
AT mwinyijessica pharmacogeneticsinprimaryheadachedisorders